Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, Petra Lührs, Caroline Thun-Hohenstein, Achim Schneeberger, Gergana Galabova, Nour K. Majbour, Nishant N. Vaikath, Omar M. A. El‐Agnaf, Dorian Winter, Eva Mihailovska, Andreas Mairhofer, Carsten Schwenke, Günther Staffler, Rossella Medori